Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
English Version English Version
  MedUni Wien  trenner  Intranet  trenner  MedUni Wien - Shop  trenner  Universitätsbibliothek  trenner  Universitätsklinikum AKH Wien  trenner
 
Krebsforschung.png
 
 
 
Hauptnavigation
  • Home
  • Mission Statement
    • Chronik
    • 50 Jahre Institut für Krebsforschung
    • Imagevideo: Institut für Krebsforschung
  • Forschung
    • Forschungsschwerpunkte
    • Forschungsgruppen
    • Wissenschaftliche Services - Core Facilities
  • Lehre
    • Vorlesungen und Seminare des Institutes
    • Universitätslehrgang Toxikologie für Postgraduierte
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Programm Malignant Diseases
    • PhD Programm Clinical and Experimental Oncology
  • Kontakt
    • Kontakt
    • Lageplan
 
Forschung / Forschungsschwerpunkte / Zelluläre und molekulare Tumorbiologie / Andrea Gsur / Biobank
 
Subnavigation
  • Forschungsschwerpunkte
    • Zelluläre und molekulare Tumorbiologie
      • Maria Sibilia
      • Robert Eferl
      • Andrea Gsur
        • Research Projects
        • Biobank
        • Group Members
      • Erich Heidenreich
      • Dietmar Herndler-Brandstetter
      • Ferdinand Steinböck
    • Angewandte und experimentelle Onkologie
    • Sicherheit chemischer Substanzen und Krebsprävention
    • Progression und Metastasierung von Tumoren
  • Forschungsgruppen
  • Wissenschaftliche Services - Core Facilities


Inhaltsbereich

Biobank

We have generated large biobanks comprising DNA, plasma and stool samples as well as clinical databases, from more than 18.000 cancer patients and controls. These biobanks, which represent a valuable resource for ongoing and future research projects. Our focus is on colorectal cancer: Colorectal Cancer Study of Austria (CORSA), prostate cancer: Prostate Cancer Study of Austria (PROSA) and lung cancer: Lung Cancer Study of Austria (LUCAS).

 

                                        

 

Colorectal Cancer Study of Austria (CORSA)

In the ongoing Colorectal Cancer Study of Austria (CORSA) more than 14.500 participants comprising colorectal cancer cases (stages I-IV), high and low risk adenomas and population-based, colonoscopy-negative controls have been recruited since 2003 in cooperation with the province-wide screening program "Burgenland Prevention Trial of Colorectal Disease with Immunological Testing" (B-PREDICT). All inhabitants of the Austrian province Burgenland aged between 40 and 80 years are invited annually to participate in fecal immunochemical testing (FIT). FIT-positive tested individuals are offered a complete colonoscopy and are asked to take part in CORSA at time of colonoscopy.
Further CRC cases have been recruited at multiple centres in Vienna such as at the Medical University of Vienna (Department of Surgery), the Clinic Favoriten Süd, Clinic Landstraße and the Medical University of Graz (Department of Internal Medicine).

Prostate Cancer Study of Austria (PROSA)

The ongoing Prostate Cancer Study of Austria (PROSA) consists of about 2.500 prostate cancer cases and 900 benign prostate hyperplasia (BPH) controls. Since 1998, patients have been recruited at the Departments of Urology at the General Hospital of Vienna (Medical University of Vienna), the Clinic Favoriten and the Clinic Donaustadt. Cases are patients with histologically verified prostate cancer. The control group comprises men with BPH.

Lung Cancer Study of Austria (LUCAS)

From January 1997 to 2006, 1.100 newly diagnosed, previously untreated and histologically confirmed lung cancer cases were recruited from the Clinic Penzing and the Landesklinikum Hochegg (Lower Austria).

 
Drucken
 
 
© MedUni Wien | Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt